WO2023067518 - PROCESS
National phase entry:
Publication Number
WO/2023/067518
Publication Date
27.04.2023
International Application No.
PCT/IB2022/060056
International Filing Date
19.10.2022
Title **
[English]
PROCESS
[French]
PROCÉDÉ
Applicants **
ASSEMBLY BIOSCIENCES, INC.
331 Oyster Point Blvd
4th Floor
South San Francisco, California 94080, US
Inventors
JOHNSON, Mark
c/o Assembly Biosciences, Inc.
331 Oyster Point Blvd
4th Floor
South San Francisco, California 94080, US
WALLACE, Michael
c/o Assembly Biosciences, Inc.
331 Oyster Point Blvd
4th Floor
South San Francisco, California 94080, US
LAGOUTTE, Roman
c/o SpiroChem AG
Rosenthal Areal WRO-1047
Mattenstrasse 22
4058 Basel, CH
BEAUD, Rodolphe
c/o SpiroChem AG
Rosenthal Areal WRO-1047
Mattenstrasse 22
4058 Basel, CH
Priority Data
63/257,697
20.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1719 | |
| EPO | Filing, Examination | 10889 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 7080 |
Total: 20857 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure generally relates to methods of synthesizing compounds useful as modulators of hepatitis B virus core protein assembly as well as novel synthetic intermediates. The methods disclosed may be used in the manufacture of compounds which may have allosteric effector properties against hepatitis B virus (HBV) core protein (Cp), a protein found as a dimer, a multimer, and as the protein shell of the HBV core. As one example, provided herein is a process for preparing compounds which may be useful for treating viral infections, such as hepatitis B.[French]
La présente invention concerne de manière générale des procédés de synthèse de composés utiles en tant que modulateurs de l'assemblage des protéines du noyau du virus de l'hépatite B ainsi que de nouveaux intermédiaires synthétiques. Les procédés décrits peuvent être utilisés dans la fabrication de composés qui peuvent avoir des propriétés effectrices allostériques contre une protéine de noyau (Cp) du virus de l'hépatite B (VHB), une protéine trouvée sous la forme d'un dimère, d'un multimère, et en tant qu'enveloppe de protéine du coeur de VHB. Par exemple, l'invention concerne un procédé de préparation de composés qui peuvent être utiles pour traiter des infections virales, telles que l'hépatite B.